Autoimmunity BioSolutions, a biotechnology company developing a personalized, genetically-guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7 receptor. Announced the close of a $1M seed extension financing round, bringing total seed capital raised to $3.1 million. The round was anchored by lead investor Eos BioInnovation and a select group of family offices whose long-term investment orientation reflects strong conviction in ABS's differentiated scientific platform and its potential to transform outcomes for the millions of autoimmune patients inadequately served by current therapies.